This study aimed to investigate the effect of chronic kidney dysfunction (CKD) 
RESUMEN

Este estudio se propuso investigar el efecto de la disfunción renal crónica (DRC) sobre las característi-cas clínicas de los pacientes con síndrome coronario agudo (SCA), y el grado de estenosis arterial coronaria. El estudio comprendió 368 pacientes con SCA sometidos a angiografía coronaria. La glucosa en sangre, la hemoglobina glicosilada (HbA1c), el colesterol total, los triglicéridos (TG), el colesterol de lipoproteína de baja densidad (LDL-C), el colesterol de lipoproteínas de alta densidad (HDL-C), el ácido úrico (AU), y la creatinina sérica fueron examinados de manera aleatoria, evaluándose la gravedad de las lesiones de la arteria coronaria mediante la puntuación de Gensini. Los pacientes fueron divididos en tres grupos según el índice de filtración glomerular estimado: función renal normal (n = 102), insuficiencia renal leve (n = 198), y disfunción renal moderada a severa (n = 68). Se analizaron las características de los pacientes con lesiones de la arteria coronaria en los tres grupos. De todos los pa
INTRODUCTION
In recent years, with the ageing population and the increasing incidence of hypertension and diabetes, the incidence of chronic kidney disease (CKD) has significantly increased. Domestic epidemiological research has shown that CKD has a high incidence rate and low awareness rate; several large-scale epidemiological investigations showed that the incidence rate of CKD was considerably high at approximately 11.8%-13%, while the awareness rate was only approximately 8.2%-9.6% (1, 2) . Research has shown that CKD is closely correlated with cardiovascular disease (CVD), and that patients with CKD have > 20% risk of developing coronary heart disease (CHD). In fact, the cause of death in most patients with CKD is not renal failure but chronic heart disease and infection. Therefore, patients with CKD stage 3 and above or CKD patients with massive proteinuria should be considered equivalent to CHD (3) . The risk of death from CVD in patients with CKD is approximately 3-10 times more than patients with normal renal function in the general population (4, 5) ; the more severe the renal dysfunction, the higher the risk of CVD death (6) . Renal dysfunction may be missed by evaluation of serum creatinine alone, therefore, we should pay particular attention to the evaluation of renal function in patients with acute coronary syndrome (ACS), in order to guide clinical treatment. At present, there are few articles on clinical features and the severity of coronary artery lesions in patients with ACS. This paper retrospectively analysed the clinical data of patients with ACS who underwent coronary angiography in the Second Artillery General Hospital, in order to investigate the clinical characteristics of patients with ACS and CKD, and to provide the theoretical support for the clinical diagnosis and treatment of these highrisk patients.
SUBJECTS AND METHODS
The study included 368 patients with ACS who underwent coronary angiography in the Department of Cardiology, the Second Artillery General Hospital from October 2010 to June 2012. Of the 368 patients, there were 122 cases of unstable angina pectoris (UAP), 29 cases of non-ST-segment elevation myocardial infarction (NSTEMI) and 217 cases of ST-elevation myocardial infarction (STEMI). The inclusion criteria were as follows: patients with ACS who had a detailed history, physical examination, electrocardiogram (ECG) and myocardial enzyme examination, and diagnostic coronary angiography. The exclusion criteria were as follows: malignant tumour, secondary hypertension, severe heart valve disease, severe liver dysfunction and acute renal dysfunction, and severe renal dysfunction requiring dialysis. This study was conducted in accordance with the Declaration of Helsinki and with approval from the Ethics Committee of the Second Artillery General Hospital of PLA. Written informed consent was obtained from all participants.
Measurements of biomarkers
Patient medical records included demographic data (gender, age), personal history of disease (hypertension, diabetes, hyperlipidaemia, kidney dysfunction), and clinical data (including coronary artery lesions and number etc). The results of tests were recorded on the first day after admission, including random blood glucose, glycated haemoglobin (HbA 1c ), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), uric acid (UA) and serum creatinine (SCr).
Estimated glomerular filtration rate (eGFR) was calculated according to SCr levels on the day of admission; eGFR (mL·min - 
Coronary angiography
Coronary angiography was performed using the Judkins' method. Coronary artery disease was defined as diameter lumen stenosis of ≥ 50% or left main stem stenosis of ≥ 40%. The left main coronary artery (LM), anterior descending branch (LAD), circumflex (LCX) and the right coronary artery (RCA) were defined as main coronary arteries. Coronary artery stenosis was evaluated using the Gensini scoring system (8) .
Statistical analysis
Measurement data are expressed as mean ± standard deviation. The data of the three groups were compared by analysis of variance and comparisons between the groups were tested by the least significant difference (LSD) test. Count data are expressed by the number of cases and percentage; χ 2 test was used between the groups and p < 0.05 was considered statistically significant. The above statistical analysis was completed with SPSS 17.0 software.
RESULTS
Clinical characteristics
As shown in Table 1 , creatinine of ≥ 106 mmol/L and ≥ 97 mmol/L for men and women, respectively, was standard in patients with ACS. There were 268 patients (72.8%) with normal renal function using the SCr standard definition. However, using the definition of eGFR ≥ 90 mL·min -1· 1.73 m -2 for normal renal function, there were only 102 cases (27.7%) with normal renal function; 53.8% of patients had mild renal insufficiency and 18.5% patients had moderate to severe renal insufficiency. The proportion of men with moderate to severe renal dysfunction was relatively reduced, and the average age of these patients was higher. There was a high ratio of patients with a history of hypertension and diabetes mellitus (p < 0.05).
DISCUSSION
Chronic kidney disease has a close relationship with CVD, and patients with ACS often have varying degrees of renal impairment. An international registry showed that the existence of CKD was at least 40% in patients with ACS (8, 9) . It was shown that eGFR can be considered an independent risk factor of ACS (10, 11) , and that decreased renal function is an independent predictor of ACS in patients with fatal and non-fatal cardiovascular events, whereby abnormal renal dysfunction after admission is indicative of short-term and long-term prognosis of patients (12) . This study also found that when renal dysfunction was defined as eGFR < 90 mL·min -1· 1.73 m -2 , 72.3% of patients with ACS had renal dysfunction. In contrast, using the SCr standard, 27.2% of patients with ACS were Hu et al Comparison of the severity of fasting plasma glucose, HbA 1c (%), serum lipid, UA and coronary artery disease As shown in Table 2 , compared with the normal renal function group, the glutamic acid (Glu), HbA 1c , TG, UA and Gensini score of patients with moderate to severe renal dysfunction were significantly increased, while HDL-C was decreased. The differences were statistically significant (p < 0.05).
defined as having renal dysfunction and therefore, the diagnosis of about half of CKD patients was missed. Currently, physicians in clinical cardiology departments evaluate renal function through SCr and therefore, the rate of clinical detection is extremely low, which has a serious impact on the diagnosis and treatment of patients with ACS complicated with CKD. Estimated GFR should be calculated early and conven- (13) . Decreased GFR level is related to adverse cardiovascular events and the rate of mortality (14) . This study found that fasting plasma glucose, HbA 1c , TG, UA and Gensini score were significantly increased, while HDL-C was significantly decreased, suggesting that severe renal dysfunction in patients with ACS is associated with more risk factors of CHD, and the severity of coronary artery lesions is more serious, which is consistent with other studies (15, 16) .
Patients with CKD are more susceptible to abnormalities in lipid metabolism than the general population. Lipid abnormality is an important factor in accelerating the progression of CKD and they are closely related. Dyslipidaemia not only increases the risk of CVD, but also accelerates the progression of renal dysfunction. Abnormal blood lipid phenotypes are not typical and specific, and can change along with the progression of the course of CKD and the degree of proteinuria. In the early stages of CKD, dyslipidaemia is mainly manifested as reduction in HDL-C and moderate increase in TG; the LDL-C level may be increased or decreased, mainly as a qualitative change, while very light density lipoproteins (in group LDL-C) may be significantly increased (17, 18) . These blood lipid changes in patients with CKD mean that the incidence of atherosclerosis is higher, and that coronary artery disease is more serious (18) . This study found that in the moderate to severe renal dysfunction group, the average LDL-C of patients was 2.92 ± 0.84 mmol/L, and that TG was increased while HDL-C was decreased significantly, which was in line with the characteristics of the abnormal lipid metabolism seen in CKD. Less dependence on the renal clearance of statins should be made in patients with ACS and renal dysfunction. The guidelines of the United Kingdom's National Institute for Health and Care Excellence recommend the use of 20 mg atorvastatin for primary prevention and two grade prevention of CVD in patients with CKD. If non-HDL-C of patients declines to < 40% and eGFR ≥ 30 mL/min/1.73 m 2 , it is proposed that the dose of atorvastatin be increased (19) . The "patient centered management of dyslipidaemia" released by the American National Lipid Association suggests that non-HDL-C is a more comprehensive related risk assessment index and a better primary target for treatment than LDL-C (20) .
Limitations of this study were that the study was retrospective, single-centre and non-randomized. Prospective, multicentre, randomized controlled clinical studies should be designed and performed in the future. Better clinical endpoints and indices should be formulated with long-term follow-up, to provide the basis for guiding clinical practice.
To summarize, early diagnosis and prevention is critical in cardiac problems. All patients with ACS should be monitored for SCr; furthermore, eGFR should be calculated according to the level of SCr, in order to more accurately determine renal function and to achieve early diagnosis and prevention of CKD.
